Last reviewed · How we verify
Belatacept 250 Milligram Intravenous Powder for Solution
Belatacept 250 Milligram Intravenous Powder for Solution is a Small molecule drug developed by Nantes University Hospital. It is currently in Phase 3 development.
At a glance
| Generic name | Belatacept 250 Milligram Intravenous Powder for Solution |
|---|---|
| Sponsor | Nantes University Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction (PHASE3)
- CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Belatacept 250 Milligram Intravenous Powder for Solution CI brief — competitive landscape report
- Belatacept 250 Milligram Intravenous Powder for Solution updates RSS · CI watch RSS
- Nantes University Hospital portfolio CI
Frequently asked questions about Belatacept 250 Milligram Intravenous Powder for Solution
What is Belatacept 250 Milligram Intravenous Powder for Solution?
Belatacept 250 Milligram Intravenous Powder for Solution is a Small molecule drug developed by Nantes University Hospital.
Who makes Belatacept 250 Milligram Intravenous Powder for Solution?
Belatacept 250 Milligram Intravenous Powder for Solution is developed by Nantes University Hospital (see full Nantes University Hospital pipeline at /company/nantes-university-hospital).
What development phase is Belatacept 250 Milligram Intravenous Powder for Solution in?
Belatacept 250 Milligram Intravenous Powder for Solution is in Phase 3.